Biogen reports better-than-expected Spinraza sales; FDA to discuss opioid prescriptions with payers; UnitedHealth Group launches media review
The FDA to study whether linking to risk information affects patient recall; patients view docs who take industry payments as less honest; Mallinckrodt ups political donations
Novartis raises Alcon forecast; UDG acquires Cambridge BioMarketing; Spark Therapeutics receives priority review for Luxturna gene therapy
AstraZeneca CEO reportedly moving to Teva; the FDA reverses on approval for Amicus drug; Merck names winners of Alexa challenge
The drugmaker is one step closer to a potential approval of its experimental cancer treatment.
Gottlieb calls for new opioid training for docs; FDA committee to examine Novartis' CAR-T therapy; no Viagra ads expected during NFL season
Drug ads on mobile are not providing enough risk info; rare-disease drugmakers are concerned about healthcare bill; volume of opioid prescriptions drops
The FDA suspends three Keytruda studies; drug and device makers gave $8 billion in payments to providers in 2016; Opdivo beat Yervoy in skin-cancer trial
The FDA plans to review orphan drug backlog; drugmaker supported charity helped patients pay for donor's drugs; low dose Xarelto gets Priority Review
Walgreens ends merger with Rite Aid; Biogen hires former Novartis exec as SVP of corporate affairs; FDA takes new measures to drive drug pricing competition
Merck announces positive trial results for CETP inhibitor; Purdue Pharma defends withholding of OxyContin marketing material; Roche's experimental haemophilia drug significantly cuts bleed rate
The performance of generic drugs is not always guaranteed; the FDA approves a new blood thinner; Gottlieb wants rejection letters public
The FDA plans public meeting to encourage generic competition; Mylan reportedly offered rebates to six Medicaid programs; Republicans to present draft bill for Obamacare replacement
The FDA recently proposed studies designed to determine how disclosures in drug ads affect how viewers frame information.
Insurance companies balk at expensive PCSK9 inhibitors; Publicis to focus investments on AI platform; clinical trial reveals Novartis' eye drug requires less frequent injections
Adamis receives FDA approval for EpiPen rival Symjepi; Clovis reports positive trial results for ovarian cancer drug Rubraca; hedge fund billionaire John Paulson joins Valeant board of directors
Apple reportedly working to bring EMRs to iPhone; FDA to study disclosures in ads; Trump admin discussing drug price EO
The FDA-approved app will allow MS patients to share their medication injection history with HCPs.
Teva gets FDA approval for Truvada generic; the FDA rejects Coherus' Neulasta biosimilar; only 17% of Americans find health industries to be innovative
The bill, introduced in March, is being considered as an amendment in the upcoming PDUFA reauthorization legislation.
50% of consumers say they will share their health data with tech giants; pharma CEOs expect pricing proposal from Trump administration; FDA approves generic versions of Strattera
FDA presents ideas to tackle drug prices; patients aware of side effects more likely to report them; scientists use Apple's Research Kit for clinical purposes
The regulator also took issue with how Orexigen Therapeutics presented the risk information
Disease awareness ads can boost drug sales; AstraZeneca's experimental asthma drug cuts steroid use; FDA approves Regeneron and Sanofi's RA drug
Amgen's osteoporosis drug set back by safety issue; new FDA digital biz to hire 13 engineers; Celgene's MS drug bests Avonex in trial
FDA requires boxed warning for J&J's Invokana; Amazon to reportedly hire GM to enter pharmacy industry; WannCry ransomware affects some health organizations
The former FDA commissioner said marketers need to focus on ensuring that off-label promotion is "non-misleading."
FDA approves Merck/Lilly combo for lung cancer; new PhRMA requirements result in expulsion of 22 members; Pfizer to pay Sangamo $7 million for gene therapy programs
The Senate confirms Gottlieb as FDA commissioner; Endo shares DTC plans for Xiaflex; an AstraZeneca asthma drug fails in late-stage study
The FDA approves osteoporosis drug; groups warn that latest healthcare bill would cut protections for pre-existing conditions; Dupixent gets PBM coverage